Photoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: a case report

BMC Family Practice

Sarina Piha-Paul³  Vivek Subbiah³  Jonathan L. Curry⁴  Anisha B. Patel²  Jennifer Goldstein¹ 

[1] Division of Cancer Medicine, Medical Oncology and Hematology Fellowship Program, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston 77030, TX, USA;Department of Dermatology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston 77030, TX, USA;Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 455, Houston 77030, TX, USA;Department of Pathology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston 77030, TX, USA

关键词: Investigational cancer therapeutics;    Tyrosine kinase inhibitor;    Metastatic follicular thyroid carcinoma;    Vandetanib;    Photoallergic reaction;   

Others  :  1142373
DOI  :  10.1186/s12895-015-0022-1

 received in 2014-10-07, accepted in 2015-01-21,  发布年份 2015

【 摘 要 】

Background

Novel targeted agents have been increasingly developed and tested in clinical trials over the past 5–10 years, many with unknown and unanticipated side effects. We describe here a case of a patient with a history of metastatic follicular thyroid carcinoma that we believe developed vandetanib–associated photoallergic dermatitis while enrolled on a phase 1 clinical trial.

Case presentation

A 51-year-old Caucasian female with poorly differentiated, metastatic follicular thyroid carcinoma presented with a cutaneous eruption that developed over 3 to 4 days while treated on phase 1 clinical trial with vandetanib-based therapy. Given the concern for photoallergic dermatitis, vandetanib was discontinued and supportive care provided including topical and oral steroid administration. Her cutaneous eruption improved and she was successfully re-challenged with vandetanib.

Conclusion

Tyrosine kinase inhibitors, such as typo-vandetinib, with various therapeutic targets have come to the forefront of oncologic therapy in recent years. It is important to have a better understanding of the side effect profile and management in order to anticipate adverse events and maintain patient safety in future clinical trials.

【 授权许可】

   
2015 Goldstein et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, et al.: ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002, 62(16):4645-55.
• [2]Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, et al.: ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002, 62(24):7284-90.
• [3]Heymach JV: ZD6474–clinical experience to date. Br J Cancer 2005, 92(Suppl 1):S14-20.
• [4]Huang X, Patel S, Ahmed N, Seiter K, Liu D: Severe toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinase inhibitors. Drug Des Devel Ther 2009, 2:215-9.
• [5]Stein KR, Scheinfeld NS: Drug-induced photoallergic and phototoxic reactions. Expert Opin Drug Saf 2007, 6(4):431-43.
• [6]Moore DE: Drug-induced cutaneous photosensitivity: incidence, mechanism, prevention and management. Drug Saf 2002, 25(5):345-72.
• [7]Rosen AC, Wu S, Damse A, Sherman E, Lacouture ME: Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis. J Clin Endocrinol Metab 2012, 97(4):1125-33.
• [8]Miller KD, Trigo JM, Wheeler C, Barge A, Rowbottom J, Sledge G, et al.: A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res 2005, 11(9):3369-76.
• [9]Kiura K, Nakagawa K, Shinkai T, Eguchi K, Ohe Y, Yamamoto N, et al.: A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol 2008, 3(4):386-93.
• [10]Chang CH, Chang JW, Hui CY, Yang CH: Severe photosensitivity reaction to vandetanib. J Clin Oncol 2009, 27(27):e114-5.
• [11]Kong HH, Fine HA, Stern JB, Turner ML: Cutaneous pigmentation after photosensitivity induced by vandetanib therapy. Arch Dermatol 2009, 145(8):923-5.
• [12]Giacchero D, Ramacciotti C, Arnault JP, Brassard M, Baudin E, Maksimovic L, et al.: A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib. Arch Dermatol 2012, 148(12):1418-20.
• [13]Fava P, Quaglino P, Fierro MT, Novelli M, Bernengo MG: Therapeutic hotline. A rare vandetanib-induced photo-allergic drug eruption. Dermatol Ther 2010, 23(5):553-5.